Charalampos Floudas, MD, DMSc, MS

Charalampos Floudas, MD, DMSc, MS
Assistant Research Physician
Genitourinary Malignancies Branch

Dr. Floudas designs and conducts early-phase clinical trials for solid tumors, focusing on head and neck cancers (HNC). He is treating patients with combinations of immunotherapy, chemotherapy and other treatment modalities. Dr. Floudas is also interested in the application of artificial intelligence and data science to omics data for immunotherapy biomarker discovery.

Areas of Expertise

1) head and neck cancer, 2) cancer immunotherapy, 3) clinical trials, 4) tumor immunology, 5) clinical computational oncology 6) artificial intelligence

Contact Info

Charalampos Floudas, MD, DMSc, MS
Center for Cancer Research
National Cancer Institute
Building 10, Room 7N240A
Bethesda, MD, 20892
Ph: 240-858-3032
charalampos.floudas@nih.gov

Dr Floudas’ research focuses in head and neck cancer and tumor immunology. He is working closely with the scientists of the Laboratory of Tumor Immunology and Biology and the Otolaryngology Surgeon-Scientists of the National Institute on Deafness and Other Communication Disorders, and is studying novel combinations of immunotherapeutic agents aiming to improve the efficacy of immunotherapy in head and neck cancers.

NIH Scientific Focus Areas:
Cancer Biology, Clinical Research, Computational Biology, Genetics and Genomics, Immunology
View Dr. Floudas's Complete Bibliography at NCBI.

Selected Key Publications

  1. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.
    Clin Colorectal Cancer. Epub ahead of print, 2019. [ Journal Article ]
  2. Immunotherapy: Current Status and Future Perspectives.
    Floudas CS, Brar G, Greten TF.
    Dig Dis Sci. 64(4): 1030–1040, 2019. [ Journal Article ]
  3. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
    Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra A.
    Front Pharmacol. 8: 49, 2017. [ Journal Article ]
  4. Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival.
    Floudas CS, Chandra AB, Xu Y.
    Melanoma Res. 26(3): 312-5, 2016. [ Journal Article ]
  5. Identifying genetic interactions associated with late-onset Alzheimer's disease.
    Floudas CS, Um N, Kamboh MI, Barmada MM, Visweswaran S.
    BioData Min. 7(1): 35, 2014. [ Journal Article ]

Dr. Floudas received his medical degree from the University of Crete, Greece, (2000), and then served as a physician in the Greek National Health System (2002) and the Greek Army (2003) . He completed an internal medicine residency at the First Department of Internal Medicine of the National University of Athens, Greece (2008), where he remained as a Research Associate of the Oncology Section (2010), and received a research doctorate in medicine from the same university (2009). After moving to the USA, he received a Master’s degree in Biomedical Informatics from the University of Pittsburgh (2012), and then he was a visiting research scholar in the Center for Health and Biomedical Informatics of the New York University (2013). He completed an internal medicine residency at the Maimonides Medical Center (Brooklyn, NY) in 2016. Subsequently, he completed a medical oncology fellowship at the NCI (2019), during which he was assistant chief fellow, and then joined the Genitourinary Malignancies Branch as an Assistant Research Physician.

Dr Floudas is a diplomate of the American Board of Internal Medicine and board certified in Medical Oncology. He has received awards from the Greek State National Merit Scholarship Program and the Gerondelis Foundation. In 2019, he received the American Society of Clinical Oncology (ASCO) GI19 Conquer Cancer Foundation Merit Award for his work in immunotherapy.

Search all
CCR clinical trials